Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation
16 mars 2020 11h51 HE
|
Meridian Bioscience Inc.
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost...
Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay
16 mars 2020 08h00 HE
|
Meridian Bioscience Inc.
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that...
Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers
26 févr. 2020 08h00 HE
|
Meridian Bioscience Inc.
CINCINNATI, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its...
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
19 févr. 2020 09h15 HE
|
Meridian Bioscience Inc.; Exalenz Bioscience
CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered...
Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance
07 févr. 2020 07h30 HE
|
Meridian Bioscience Inc.
CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020...
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
27 janv. 2020 09h17 HE
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named...
Meridian เปิดตัวพอลิเมอเรสความแม่นยำสูงแบบใหม่เพื่อให้การเพิ่มจำนวนที่แข็งแกร่งสำหรับประโยชน์ในงานวิเคราะห์ NGS และ PCR
23 janv. 2020 16h46 HE
|
Meridian Bioscience Inc.
ซินซินนาติ, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) ได้ประกาศในวันนี้ถึงการเปิดตัว High-Specificity Pfu HS Mix ซึ่งไม่เพียงแต่ให้การเพิ่มปริมาณที่มีความแม่นยำสูง...
メリディアン、NGSおよびPCRアプリケーション向けの確実な増幅を実現する新しいハイフィデリティ･ポリメラーゼを公開
23 janv. 2020 16h46 HE
|
Meridian Bioscience Inc.
シンシナティ発, Jan. 24, 2020 (GLOBE NEWSWIRE) -- メリディアン･バイオサイエンス (Meridian Bioscience, Inc.、NASDAQ: VIVO) は本日、High-Specificity Pfu HS Mixを発表した。これはハイフィデリティ増幅を実現するだけでなく、コンパニオン診断 (CDx)...
Meridian bietet mit neuer High-Fidelity-Polymerase stabile Amplifikation für NGS- und PCR-Anwendungen
23 janv. 2020 16h46 HE
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) hat heute die Einführung eines High-Specificity Pfu HS Mix bekanntgegeben, der neben einer...
Meridian 推出一種新的高保真聚合酶，可為 NGS 和 PCR 應用提供可靠的擴增
23 janv. 2020 16h46 HE
|
Meridian Bioscience Inc.
辛辛那提, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) 今天宣佈推出高特異性 Pfu HS Mix，不但可提供高保真擴增，而且提供具有市場領先地位的擴增，用於伴隨診斷 (CDx) 和臨床測試。 高保真擴增對於結果取決於正確 DNA 序列的應用至關重要，例如下一代測序...